CDEK
← All drugs Report issue

remoxipride

Small moleculeexperimental

Clinical trial activity

0 trials · 0 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Mechanism of action

  • Dopamine D2 receptorANTAGONIST

    DRD2 antagonist

    Remoxipride binds specifically to the D2 receptor and has little affinity for other central receptors e.g. adrenergic, muscarinic and 5-HT receptors. Therefore, the incidence of adverse effects is less than with other antipsychotics. Dopamine binding to the D2 receptor inhibits the prolactin release from the pituitary into plasma, and therefore, D2 antagonism induces its release.

Chemistry & pharmacology

Loading structure…

SMILES

CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC.Cl.O
Mol. weight
425.75 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • a-33547
  • a-33547
  • a-33547.hcl.h20
  • a-33547.hcl.h20
  • fla-731
  • fla-731
  • fla-731(-)
  • fla-731(-)
  • remoxiprida
  • remoxiprida
  • remoxipride
  • remoxipride
  • remoxipride
  • remoxipride
  • remoxipride
  • remoxipride
  • remoxipride
  • remoxipride
  • remoxipride hcl
  • remoxipride hcl
  • remoxipride hcl
  • remoxipride hydrochloride
  • remoxipride hydrochloride
  • remoxipride hydrochloride
  • remoxipridum
  • remoxipridum
  • roxiam
  • roxiam
  • roxiam ir
  • (s)-remoxipride